Original article
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

https://doi.org/10.1016/1078-1439(95)00041-FGet rights and content

Abstract

To compare the toxicity and efficacy of intravesical bacillus Calmette-Guérin (BCG) immunotherapy and mitomycin C (MMC) chemotherapy in the prophylaxis of recurrent transitional cell carcinoma, 469 patients with completely resected stage Ta or TI transitional cell carcinoma were enrolled in a randomized Southwest Oncology Group Phase III study. All patients were judged to be at increased risk for tumor recurrence due to having had two occurrences of tumor within 56 weeks, stage T I tumor or three or more tumors within 16 weeks, or concurrent carcinoma in situ. Three hundred and seventy-seven evaluable patients received either 50 mg of Tice BCG in 50 cc saline or 20 mg MMC in 20 cc water weekly for 6 weeks and then monthly to one year. Local and systemic grade I and 2 toxicity was seen significantly more frequently following BCG treatment (P = 0.003), but no life threatening toxicity was seen with either treatment. Recurrence-free survival was significantly prolonged (P = 0.017, proportional hazard regression) in patients randomized to the BCG arm compared to the MMC arm, but there were no statistically significant differences at this analysis for worsening-free survival and overall survival, although the number of these events is too low for a definitive analysis of these long-term outcomes. Therefore, when compared to MMC chemotherapy, BCG immunotherapy is associated with a significantly higher frequency of grade 1 and 2 adverse reactions and a significantly lower first recurrence hazard rate.

References (25)

  • J.A. Martinez-Pineiro et al.

    Intravesical therapy comparing BCG, Adriamycin, and Thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study

    Progress in Clinical and Biological Research

    (1989)
  • D.L. Lamm et al.

    A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the Bladder

    N Engl J Med

    (1991)
  • Cited by (119)

    • Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG

      2022, Urologic Oncology: Seminars and Original Investigations
      Citation Excerpt :

      After a median 15 month follow up, the 2-year RFS was dismal in both the gemcitabine (19%) and BCG (3%) groups. A multitude of other salvage therapy studies have been reported, including gemcitabine [22], mitomycin C [23], docetaxel [24], epirubicin [25], and gemcitabine with mitomycin C [26,27], but none included a pure population that received a single BCG induction course; rather, all assessed mixed cohorts with heterogeneous stage and prior treatment history. Our study is the first to assess outcomes of Gem/Doce specifically in the subset of patients who recur after a single induction course of BCG.

    • The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1

      2018, Urologic Oncology: Seminars and Original Investigations
      Citation Excerpt :

      Although the precise mechanism of action of BCG immunotherapy remains the subject of continued investigation, it is believed to function by activating both the innate and adaptive immune systems [7]. Intravesical BCG has been validated by multiple randomized controlled trials as a superior therapy to intravesical chemotherapy including mitomycin and epirubicin [8–11]. Since its introduction nearly 4 decades ago, BCG is still considered to be one of the most successful immunotherapy agents for any solid malignancy [12].

    View all citing articles on Scopus

    This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA46113, CA22433 CA13612, CA42777, CA46441, CA46282, CA13238, CA45560, CA20319, CA27057, CA16385, CA28862, CA35192, CA35431, CA12213, CA22411, CA35090, CA32734, CA35178, CA35281, CA14028, CA35261, CA35117, CA45450, CA52420, CA37981, CA04919, CA36020, CA38926, CA32102, CA49957, CA21076.

    View full text